Alcami Announces Manufacturing Agreement for Solasia’s API Darinaparsin

Alcami announces that it has finalized manufacturing and quality agreements with Solasia Pharma, K.K. (TSE: 4597) for the clinical supply manufacture of the active pharmaceutical ingredient (API) darinaparsin, a novel mitochondrial-targeted agent developed for the treatment of various hematologic and solid cancers.

Solasia is a Japan-based specialty pharmaceutical company dedicated to the development of innovative oncology medicines. In March 2011, Solasia acquired the rights to darinaparsin from ZIOPHARM Oncology, Inc. for the potential treatment of Peripheral T-Cell Lymphoma (PTCL). The agent is currently in Phase II pivotal trials in Asia.

“We are pleased to entrust Alcami with this project,” said Mr. Yoshihiro Arai, President and CEO of Solasia Pharma, K.K. “Finding a responsible partner for the development and manufacturing of our API was a significant step in our clinical program.”

Process development for darinaparsin and clinical manufacturing will begin within Alcami’s new highly potent API suites in Q4 2017, located at its API Center of Excellence facility in Germantown, Wisconsin.

“We are extremely grateful for the opportunity to partner with Solasia as the trusted supplier of darinaparsin. Our relationship is an excellent example of Alcami’s dedication to delivering reliable and high quality medicines across the globe. As we continue to grow our established business in Japan, we look forward to supporting Solasia for its future clinical and commercial success,” stated Syed T. Husain, Chief Commercial Officer of Alcami.